STRATA Skin Sciences Q3 rev $8.8M, first non-GAAP operating profit since 2018

STRATA Skin Sciences, Inc.

2024-Q3 EPS reported -$1.52 revenue$23,986,000

Revenue $8.8M (-1% YoY); recurring revenue $5.4M (+2% YoY); gross margin 60.3% (up from 56.0% YoY).
Non-GAAP operating profit $128K (excl. $1.8M NY tax accrual); first since 2018 refinancing.
Net loss narrowed to $0.3M ($0.08/sh) from $1.1M ($0.30/sh) in Q3 2023; cash $8.4M.
XTRAC domestic base 873 (down from 882 Q2); TheraClear X base 135 (up from 117 Q2).
Designated John Gillings (VP Finance) as principal financial & accounting officer; raised $2.1M in July equity offering.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Gillings

principal financial officer and principal accounting officer

SSKN · STRATA Skin Sciences, Inc.

Effective: 2024-11-13
Filed: November 13, 2024, 6:59 PM ET

On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Gillings was appointed as principal financial officer and principal accounting officer at STRATA Skin Sciences, Inc..

Action: designated
Role: principal financial officer and principal accounting officer

Exact text from the filing

On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer.

View on SEC.gov

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-046508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.